ARTIVION, INC. AORT
ARTIVION, INC. (AORT) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.30% (safety: no dividend). FY2025 revenue was $441.3M at a 2.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.44 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.29 |
| Retained earnings / assets | -0.058 |
| EBIT / assets | 0.038 |
| Equity / liabilities | 1.027 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AORT | ARTIVION, INC. | 7/9 | 3.05 | 117.3 | +13.6% |
| ARAY | ACCURAY INC | 6/9 | -1.53 | — | +2.7% |
| MDXG | MIMEDX GROUP, INC. | 5/9 | 8.06 | 12 | +20% |
| GKOS | GLAUKOS Corp | 2/9 | 0.74 | — | +32.3% |
| ATRC | AtriCure, Inc. | 7/9 | 3.44 | — | +14.9% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 7/9 | 8.52 | 35.8 | +12.5% |
| ANGO | ANGIODYNAMICS INC | 5/9 | -1.82 | — | +9.5% |
About ARTIVION, INC.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
FAQ
Is AORT financially healthy?
ARTIVION, INC.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does AORT pay a dividend, and is it safe?
Yes. ARTIVION, INC. pays a dividend yielding about 0.30% with a None payout ratio, rated “no dividend” for safety.
How profitable is AORT?
In FY2025, ARTIVION, INC. had a net margin of 2.2% and a return on equity of 2.2%.
Is AORT overvalued or undervalued?
ARTIVION, INC. trades at about 136.4× trailing earnings — above its 10-year norm (10-year range 18.9×–594.8×, median 59.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for AORT?
The average Wall-Street price target for ARTIVION, INC. is $42.00, about 46.6% above the recent price, from 8 analysts (consensus: strong buy).
Is AORT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ARTIVION, INC.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 117.3×, a dividend yield of 0.30%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.